These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28763329)

  • 1. Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.
    Machida H; Moeini A; Ciccone MA; Mostofizadeh S; Takiuchi T; Brunette LL; Roman LD; Matsuo K
    Am J Clin Oncol; 2018 Sep; 41(9):851-860. PubMed ID: 28763329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.
    Song M; DiPaola RS; Cracchiolo BM; Gibbon DG; Hellmann M; Nieves-Neira W; Vaidya A; Wagreich AR; Shih WJ; Rodriguez-Rodriguez L
    Int J Gynecol Cancer; 2014 Nov; 24(9):1636-41. PubMed ID: 25304678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.
    Hisamatsu T; Mabuchi S; Yoshino K; Fujita M; Enomoto T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2012 May; 22(4):623-9. PubMed ID: 22343974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line paclitaxel and carboplatin in persistent/recurrent or advanced cervical cancer: a retrospective analysis of patients treated at Brazilian National Cancer Institute.
    Garces ÁH; Mora PA; Alves FV; do Carmo CC; Grazziotin R; Fernandes AC; Nogueira-Rodrigues A; de Melo AC
    Int J Gynecol Cancer; 2013 May; 23(4):743-8. PubMed ID: 23552805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
    Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
    Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel as a first-line chemotherapy for Japanese women with advanced or recurrent breast cancer: a multi-institutional practice-based study by the Kyushu Breast Cancer Study Group (KBC-SG).
    Ishikawa M; Takamatsu Y; Mitsuyama S; Iwakuma N; Anan K; Umeda S; Tamura K
    Breast Cancer; 2010 Apr; 17(2):131-5. PubMed ID: 19472037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G; Fei F; Mangioni C
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy.
    Mabuchi S; Morishige K; Fujita M; Tsutsui T; Sakata M; Enomoto T; Kimura T
    Gynecol Oncol; 2009 May; 113(2):200-4. PubMed ID: 19268342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma.
    Matsuo K; Ross MS; Yunokawa M; Johnson MS; Machida H; Omatsu K; Klobocista MM; Im DD; Satoh S; Baba T; Ikeda Y; Bush SH; Hasegawa K; Blake EA; Takekuma M; Shida M; Nishimura M; Adachi S; Pejovic T; Takeuchi S; Yokoyama T; Ueda Y; Iwasaki K; Miyake TM; Yanai S; Nagano T; Takano T; Shahzad MMK; Ueland FR; Kelley JL; Roman LD
    Gynecol Oncol; 2017 Dec; 147(3):565-571. PubMed ID: 29056442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.
    McLachlan J; Boussios S; Okines A; Glaessgen D; Bodlar S; Kalaitzaki R; Taylor A; Lalondrelle S; Gore M; Kaye S; Banerjee S
    Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):153-160. PubMed ID: 27838135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer.
    Yin M; Zhang H; Li H; Li X; Liu Y; Chen X; Lou G; Li K
    J Surg Oncol; 2012 Feb; 105(2):206-11. PubMed ID: 21815150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix.
    Sit AS; Kelley JL; Gallion HH; Kunschner AJ; Edwards RP
    Cancer Invest; 2004; 22(3):368-73. PubMed ID: 15493357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity.
    Manders DB; Kehoe SM; Miller DS; Lea JS; Richardson DL
    Am J Clin Oncol; 2018 Aug; 41(8):797-801. PubMed ID: 28225444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of prognostic factors and therapeutic patterns of recurrent stage Ⅰb-Ⅱa cervical squamous carcinoma treated with radical hysterectomy].
    Ou ZJ; Zhao D; An JS; Sun CY; Huang MN; Li B; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2019 Jun; 54(6):399-405. PubMed ID: 31262124
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma.
    Li Y; Zeng J; Huang M; An J; Bai P; Wu L; Zhang R
    Cancer; 2017 Feb; 123(3):420-425. PubMed ID: 27696395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix.
    Eralp Y; Saip P; Sakar B; Tas F; Aydiner A; Topuz E
    Eur J Gynaecol Oncol; 2003; 24(3-4):323-6. PubMed ID: 12807249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: has this regimen still a role as neoadjuvant setting?
    Moioli M; Papadia A; Mammoliti S; Pacella E; Menoni S; Menada MV; Ragni N
    Minerva Ginecol; 2012 Apr; 64(2):95-107. PubMed ID: 22481620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term curative effect and safety of bevacizumab combined with chemotherapy for treating recurrent and metastatic cervical cancer.
    Xiao Y; Cheng HJ; Wang L; Luo SX
    Eur J Gynaecol Oncol; 2017; 38(1):76-79. PubMed ID: 29767869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
    Takekuma M; Hirashima Y; Ito K; Tsubamoto H; Tabata T; Arakawa A; Itani Y; Furukawa N; Murakoshi H; Takeuchi S
    Gynecol Oncol; 2012 Sep; 126(3):341-5. PubMed ID: 22609108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.
    Kim JS; Kim JS; Kim SY; Kim Ki; Cho MJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1247-53. PubMed ID: 12654434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.